β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.

ABSTRACT:

Objective

This study was undertaken to examine the association between montelukast use, β2-adrenoreceptor (β2AR) agonist use, and later Parkinson disease (PD).

Methods

We ascertained use of β2AR agonists (430,885 individuals) and montelukast (23,315 individuals) from July 1, 2005 to June 30, 2007, and followed 5,186,886 PD-free individuals from July 1, 2007 to December 31, 2013 for incident PD diagnosis. We estimated hazard ratios and 95% confidence intervals using Cox regressions.

Results

We observed 16,383 PD cases during on average 6.1 years of follow-up. Overall, use of β2AR agonists and montelukast were not related to PD incidence. A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary diagnosis.

In

SUBMITTER: Liu B 

PROVIDER: S-EPMC11497350 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature